XM अमेरिका के निवासियों को अपनी सेवाएँ मुहैया नहीं करता है।
P
P

Pfizer


समाचार

Regeneron loses key defense in 19 treatment patent lawsuit

Regeneron loses key defense in COVID-19 treatment patent lawsuit By Blake Brittain Oct 4 - Biotech company Regeneron Pharmaceuticals REGN.O lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. U.S. District Judge Philip Halpern rejected Regeneron's pretrial argument that he should throw out Allele Biotechnology and Pharmaceuticals' patent lawsuit over the treatment based on a federal law allowing the use of patented invent
P
R

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou
A
B
C
G
N
P

Greece is unlikely victor in bank selldown race

BREAKINGVIEWS-Greece is unlikely victor in bank selldown race The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Liam Proud LONDON, Oct 3 (Reuters Breakingviews) - In 2010, it was hard to imagine the day when Greece's banking sector would be fully privatised and thriving. That was the year the government founded the Hellenic Financial Stability Fund (HFSF) to prop up ailing lenders.
C
E
M
P
U
A
A
P

Moderna fends off Alnylam US patent lawsuit over COVID shots, for now

Moderna fends off Alnylam US patent lawsuit over COVID shots, for now By Blake Brittain Oct 2 (Reuters) - Alnylam Pharmaceuticals ALNY.O admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's MRNA.O blockbuster COVID-19 vaccines of infringing one of its patents. Alnylam and Moderna told U.S. District Judge Colm Connolly in a joint filing on Wednesday that Alnylam could not win its case after the judge interpreted part of the patent in a way that favored Moderna.
P

WHO recommends maternal vaccine and antibody shot to prevent RSV in infants

UPDATE 1-WHO recommends maternal vaccine and antibody shot to prevent RSV in infants Adds comments from WHO press conference in paragraphs 7 to 10 By Kashish Tandon and Bhanvi Satija Oct 1 (Reuters) - The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV) infection in newborns.
A
G
P
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Berkshire Hathaway, Brembo, Macquarie, SumUp; Updates: PepsiCo Oct 1 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1945 GMT on Tuesday: ** Berkshire Hathaway BRKa.N will take full ownership of Berkshire Hathaway Energy, after Warren Buffett's conglomerate agreed to acquire the 8% it did not already own from the family of late billionaire philanthropist Walter Scott.
B
N
P
P
Q
R
I
P

WHO recommends maternal shot and antibody therapy to prevent RSV in infants

WHO recommends maternal shot and antibody therapy to prevent RSV in infants Oct 1 (Reuters) - The World Health Organization on Tuesday recommended maternal vaccination and the use of an antibody therapy to prevent respiratory synctial virus (RSV) in infants. The recommendations, to administer both the shot and the antibody or either, come after the WHO's strategic advisory group on immunization met last week.
A
G
P
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 1 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Tuesday: ** Dutch crop trader Louis Dreyfus raised its buyout offer for Namoi Cotton, with its bid that values the Australian cotton ginning firm at A$159.3 million ($110 million), signalling the end of a months-long bidding war as Singapore's Olam Agri effectively surrendered arms.
N
P
P
Q
R
I

UK Stocks-Factors to watch on Oct 1

UPDATE 1-UK Stocks-Factors to watch on Oct 1 Adds new items, updates futures Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0 .4%. * HALEON: Pfizer PFE.N offloaded shares worth roughly $3.26 billion in Haleon HLN.L at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said.
A
G
P
R

Europe before the bell: futures steady, M&A on the radar

LIVE MARKETS-Europe before the bell: futures steady, M&A on the radar Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: FUTURES STEADY, M&A ON THE RADAR European shares look set to steady on Tuesday following a negative finish to the third quarter on Monday, when warnings from Stellantis STLAM.MI , VW VOWG_p.DE and Aston Martin AML.L raised fresh concern ove
P
V
A
E
F
U
G

Haleon To Purchase Shares Worth 230 Mln Stg From Pfizer

BRIEF-Haleon To Purchase Shares Worth 230 Mln Stg From Pfizer Oct 1 (Reuters) - HALEON PLC HLN.L : HALEON PLC - UPDATE ON PURCHASE ALONGSIDE PFIZER OFFERING HALEON PLC - TO PURCHASE 60,526,315 SHARES FROM PFIZER HALEON PLC - PURCHASE PRICE £3.80 PER SHARE, TOTAL £230 MILLION Source text for Eikon: ID:nRSA3613Ga Further company coverage: HLN.L
P

Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon

Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon Oct 1 (Reuters) - Pfizer PFE.N offloaded shares worth roughly $3.26 billion in Haleon HLN.L at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday. Reporting by Prerna Bedi in Bengaluru; Editing by Savio D'Souza
P

UK Stocks-Factors to watch on Oct 1

UK Stocks-Factors to watch on Oct 1 Oct 1 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0.34% * HALEON: Pfizer's PFE.N stake sale in British consumer healthcare company Haleon HLN.L has been upsized by 100 million shares to 640 million shares worth about $3.25 billion with strong demand from investors, a bookrunner familiar with the offering said on Monday.
A
P

Bookrunner Says Haleon PLC ABB Sale Of Shares By Pfizer Inc Deal Upsized To 640MM Shares / C. USD 3.25bn

BRIEF-Bookrunner Says Haleon PLC ABB Sale Of Shares By Pfizer Inc Deal Upsized To 640MM Shares / C. USD 3.25bn Sept 30 (Reuters) - Bookrunner: BLOCK TRADE: HALEON PLC ABB (SECONDARY) SALE OF SHARES BY PFIZER INC - DEAL UPSIZED TO 640MM SHARES / C. USD 3.25BN - BOOKRUNNER BLOCK TRADE: HALEON PLC ABB SALE OF SHARES BY PFIZER INC - ORDERS BELOW GBP 3.
P

Bookrunner Says Haleon Secondary ABB's Sale Of Shares By Pfizer Books Are Covered

BRIEF-Bookrunner Says Haleon Secondary ABB's Sale Of Shares By Pfizer Books Are Covered Sept 30 (Reuters) - BOOKRUNNER: BLOCKTRADE- HALEON PLC ABB (SECONDARY) - SALE OF SHARES BY PFIZER INC; BOOKS ARE COVERED; FURTHER GUIDANCE TO FOLLOW - BOOKRUNNER Further company coverage: HLN.L
P

Haleon To Buy £230 Mln Worth Of Shares From Pfizer

BRIEF-Haleon To Buy £230 Mln Worth Of Shares From Pfizer Sept 30 (Reuters) - HALEON PLC HLN.L : HALEON PLC - PROPOSED PURCHASE ALONGSIDE PFIZER OFFERING HALEON PLC - TO PURCHASE £230 MILLION WORTH OF SHARES FROM PFIZER Source text for Eikon: ID:nRSd3182Ga Further company coverage: HLN.L
P

Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says

UPDATE 3-Drug giant Pfizer sells $3.3 bln stake in Sensodyne-maker Haleon Placing at a 3.3% discount to Haleon's last close Haleon to buy back 230 mln stg worth of shares from Pfizer Pfizer to remain top Haleon shareholder -LSEG data Updates dateline to Oct. 1, recasts with final pricing, shares, other details throughout By Shanima A Oct 1 (Reuters) - Pfizer PFE.N sold a stake in British consumer healthcare group Haleon HLN.L worth about $3.26 billion on Monday, cutting its shareholding in the m
G
G
P

Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner

Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner Sept 30 (Reuters) - Pfizer PFE.N intends to offload about 540 million shares in the British consumer healthcare company Haleon HLN.L , a bookrunner said on Monday. The proposed sale will reduce the top shareholder's interest in Sensodyne-maker Haleon to 16.2% from 22.6%. Reporting b
P



स्थितियाँ

लोकप्रिय परिसंपत्तियाँ

अस्वीकरण: XM Group के सत्व केवल निष्पादन वाली सेवा और हमारी ऑनलाइन व्यापार सुविधा में पहुँच प्रदान करते हैं, ताकि व्यक्ति वेबसाइट पर या उसके जरिए उपलब्ध सामग्री को देख सके और/या उसका उपयोग कर सके। इसका प्रयोजन इसे बदलना या विस्तार देना नहीं है, न ही वह इसे बदलता या विस्तार देता है। इस तरह की पहुँच हमेशा ही निम्नलिखित के अधीन रहेगी: (1) नियम और शर्तें; (2) जोखिम चेतावनियाँ; और (3) पूर्ण अस्वीकरण। इसलिए ऐसी जानकारी सामान्य सूचना से अधिक कुछ भी नहीं है। विशेष रूप से, कृपया इससे अवगत रहें कि हमारी ऑनलाइन व्यापार सुविधा की सामग्रियाँ न तो किसी चीज का अनुरोध करती हैं, न ही वित्तीय बाजारों में प्रवेश करने की पेशकश ही करती हैं। किसी भी वित्तीय बाजार में व्यापार करने के साथ आपकी पूँजी को उल्लेखनीय जोखिम है।

हमारी ऑनलाइन व्यापार सुविधा में प्रकाशित सभी सामग्रियाँ शैक्षणिक/सूचनात्मक प्रयोजनों मात्र के लिए हैं, और इनमें वित्तीय, निवेश टैक्स या व्यापार सलाह और सुझाव नहीं हैं - न ही ऐसा समझना चाहिए कि इनमें ये सब हैं; न ही इनमें हमारी व्यापार कीमतों का अभिलेख है; न ही इनमें किसी वित्तीय उपकरण में लेन-देन करने का निमंत्रण या अनुरोध है; न ही ये आपको अवांछित वित्तयी प्रोमोशन पेश करती हैं।

इस वेबसाइट में मौजूद कोई भी तृतीय पक्षीय सामग्री, तथा XM द्वारा तैयार की गई सामग्रियाँ, जैसे: अभिप्राय, समाचार, अनुसंधान, विश्लेषण, कीमतें और अन्य सूचनाएँ या तृतीय पक्षों की साइटों के लिंक, "जैसा-है-वैसा" के आधार पर बाजार के बारे में सामान्य टिप्पणी के रूप में उपलब्ध कराई गई हैं, और वे निवेश हेतु सलाह नहीं हैं। जिस हद तक कीसी सामग्री को निवेश अनुसंधान मान लिया जाता है, उस हद तक आपको ध्यान में रखना होगा और इसे स्वीकार करना होगा कि वह सामग्री इस उद्देश्य से और निवेश अनुसंधान की स्वतंत्रता को बढ़ावा देने के लिए कानूनी आवश्यकताओं के मुताबिक, तैयार नहीं की गई है, और इसलिए उसे प्रासंगिक कानूनों और विनियमों के तहत विपणन संप्रेषण माना जाएगा। कृपया सुनिश्चित करें कि आपने गैर-आश्रित निवेश के बारे में हमारी सूचना को पढ़ और समझ लिया है। पीछे दी गई जानकारी के बारे में अनुसंधान और जोखिम चेतावनी यहाँ उपलब्ध है।

जोखिम की चेतावनी: आपकी पूँजी जोखिम में है। लीवरेज वाले उत्पाद सबके उपयुक्त नहीं होते हैं। कृपया हमारे जोखिम खुलासे पर विचार करें।